Review



male scid beige mice  (Charles River Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Charles River Laboratories male scid beige mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Male Scid Beige Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/male scid beige mice/product/Charles River Laboratories
    Average 86 stars, based on 1 article reviews
    male scid beige mice - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association"

    Article Title: A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association

    Journal: Translational Oncology

    doi: 10.1016/j.tranon.2026.102819

    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male immunodeficient SCID/Beige mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Figure Legend Snippet: Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male immunodeficient SCID/Beige mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.

    Techniques Used: Activity Assay, In Vivo, Control, Western Blot, Transformation Assay, Two Tailed Test



    Similar Products

    male scid beige mice  (Charles River Laboratories)
    86
    Charles River Laboratories male scid beige mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Male Scid Beige Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/male scid beige mice/product/Charles River Laboratories
    Average 86 stars, based on 1 article reviews
    male scid beige mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    male nod scid gamma nsg mice  (Jackson Laboratory)
    86
    Jackson Laboratory male nod scid gamma nsg mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Male Nod Scid Gamma Nsg Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/male nod scid gamma nsg mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    male nod scid gamma nsg mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    nod scid gamma nsg carrier mice  (Jackson Laboratory)
    86
    Jackson Laboratory nod scid gamma nsg carrier mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Nod Scid Gamma Nsg Carrier Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nod scid gamma nsg carrier mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    nod scid gamma nsg carrier mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    female nod cb17 prkdc scid j nod scid mice  (Jackson Laboratory)
    86
    Jackson Laboratory female nod cb17 prkdc scid j nod scid mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Female Nod Cb17 Prkdc Scid J Nod Scid Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/female nod cb17 prkdc scid j nod scid mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    female nod cb17 prkdc scid j nod scid mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    mouse nod scid mice females  (Huachuang Securities Co Ltd)
    86
    Huachuang Securities Co Ltd mouse nod scid mice females
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Mouse Nod Scid Mice Females, supplied by Huachuang Securities Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse nod scid mice females/product/Huachuang Securities Co Ltd
    Average 86 stars, based on 1 article reviews
    mouse nod scid mice females - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    scid mice cb17 icr prkdcscid icrlcocrl  (Charles River Laboratories)
    86
    Charles River Laboratories scid mice cb17 icr prkdcscid icrlcocrl
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Scid Mice Cb17 Icr Prkdcscid Icrlcocrl, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scid mice cb17 icr prkdcscid icrlcocrl/product/Charles River Laboratories
    Average 86 stars, based on 1 article reviews
    scid mice cb17 icr prkdcscid icrlcocrl - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    female nod scid il2rg null nsg mice  (Shanghai Model Organisms Center)
    86
    Shanghai Model Organisms Center female nod scid il2rg null nsg mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Female Nod Scid Il2rg Null Nsg Mice, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/female nod scid il2rg null nsg mice/product/Shanghai Model Organisms Center
    Average 86 stars, based on 1 article reviews
    female nod scid il2rg null nsg mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    nod scid gamma nsg mice  (Jackson Laboratory)
    86
    Jackson Laboratory nod scid gamma nsg mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Nod Scid Gamma Nsg Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nod scid gamma nsg mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    nod scid gamma nsg mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    nod cb17 prkdcscid j nod scid mice  (Jackson Laboratory)
    86
    Jackson Laboratory nod cb17 prkdcscid j nod scid mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Nod Cb17 Prkdcscid J Nod Scid Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nod cb17 prkdcscid j nod scid mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    nod cb17 prkdcscid j nod scid mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    female nod cg prkdc scid il2rg tm1wjl szj nsg mice  (Jackson Laboratory)
    86
    Jackson Laboratory female nod cg prkdc scid il2rg tm1wjl szj nsg mice
    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male <t>immunodeficient</t> <t>SCID/Beige</t> mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
    Female Nod Cg Prkdc Scid Il2rg Tm1wjl Szj Nsg Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/female nod cg prkdc scid il2rg tm1wjl szj nsg mice/product/Jackson Laboratory
    Average 86 stars, based on 1 article reviews
    female nod cg prkdc scid il2rg tm1wjl szj nsg mice - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male immunodeficient SCID/Beige mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.

    Journal: Translational Oncology

    Article Title: A RIPK2 activity signature in prostate cancer: Modulation by RIPK2 inhibition and clinical association

    doi: 10.1016/j.tranon.2026.102819

    Figure Lengend Snippet: Ponatinib progressively suppresses the RIPK2 activity signature in vivo. (A) Schematic of the in vivo experimental design. Male immunodeficient SCID/Beige mice bearing ∼200 mm 3 subcutaneous (s.c.) 22Rv1 xenograft tumors were treated daily with ponatinib (Pon, 6 mg/kg) or vehicle (Veh) control by oral gavage for 3 or 7 days. Created with BioRender.com. (B) Tumor weights of 22Rv1 xenografts harvested after 3 or 7 days of treatment (n = 3 mice per group). (C) Immunoblot images (left) and corresponding densitometric quantification (right) of the indicated proteins in xenograft tumor lysates (n = 3). (D) Grouped dot plot showing log 2 -transformed fold changes (Log 2 FC) of the indicated RIPK2 signature genes in xenograft tumors relative to vehicle controls (n = 3). (E) Swarm plot of RIPK2 qPCR signature scores in xenografts (n = 3). Solid lines represent the mean signature scores. Nominal P-values were calculated using an unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.

    Article Snippet: A total of 100 μL of the cell suspension was injected subcutaneously into one flank of 6-week-old male SCID/Beige mice (n = 12; Charles River, #CRL:250; CB17.Cg-Prkdc scid Lyst bg-J /Crl).

    Techniques: Activity Assay, In Vivo, Control, Western Blot, Transformation Assay, Two Tailed Test